URGN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
89.0M
+22.8%
72.5M
+42.2%
51.0M
+34.7%
37.8M
+37.7%
27.5M
Cost of Revenue
7.5M
+14.2%
6.6M
+58.8%
4.1M
+25.8%
3.3M
+0.3%
3.3M
Gross Profit
81.5M
+23.7%
65.9M
+40.7%
46.8M
+35.5%
34.5M
+42.7%
24.2M
Operating Expenses
73.2M
+11.2%
65.8M
-2.0%
67.1M
+25.0%
53.7M
+4.0%
51.6M
R&D
26.0M
+49.8%
17.3M
+11.1%
15.6M
+9.0%
14.3M
+2.2%
14.0M
SG&A
47.2M
-2.5%
48.4M
-5.9%
51.5M
+30.8%
39.3M
+4.7%
37.6M
Operating Income
8.3M
+7403.6%
111.0K
+100.5%
-20263000
-6.0%
-19115000
+30.2%
-27386000
EBITDA
8.4M
+4349.7%
189.0K
+100.9%
-20188000
-6.0%
-19040000
+30.3%
-27306000
Net Income
-1462000
+89.8%
-14351000
+39.1%
-23574000
+10.6%
-26364000
+20.9%
-33347000
EPS (Basic)
$-0.03
+89.3%
$-0.28
+40.4%
$-0.47
+13.0%
$-0.54
+21.7%
$-0.69
EPS (Diluted)
$-0.03
+89.3%
$-0.28
+40.4%
$-0.47
+13.0%
$-0.54
+21.7%
$-0.69
Shares (Diluted)
50.6M
+0.4%
50.4M
+0.4%
50.2M
+1.9%
49.2M
+2.5%
48.1M
UroGen Pharma (URGN) — Financials